Archive for the ‘Health Care Stocks’ Category

List of stem cell stocks

Monday, March 9th, 2009

Here’s a great list of companies specializing in stem cell research. The list was originally published here. Some of the companies on the original list are no longer around.

The list below is more accurate than the original.

Aastrom Biosciences Inc. (Nasdaq: ASTM)
Develops patient-specific products for the repair or regeneration of human tissues, using proprietary adult stem cell technology.

AVI Biopharma (Nasdaq: AVII)
A biopharmaceutical company developing drugs to treat life-threatening diseases using third-generation antisense technology.

BrainStorm Cell (Nasdaq: BCLI)
Developer of stem cell therapeutic products based on breakthrough technologies, including their core technology, NurOwn™.

Cord Blood America Inc. (OTCBB: CBAI)
Provides collection, testing, processing, and preservation services of the blood of umbilical cords.

CRYO-CELL (Nasdaq: CCEL)
The world’s oldest & largest family cord blood stem cell bank, for expectant parents for the private collection, processing & cryopreservation of their newborn’s non-controversial U-Cord® stem cells.

Cytori Therapeutics (Frankfurt: XMPA)
Develops proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat, and developed developed its proprietary Celution(TM) System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour.
Geron (Nasdaq: GERN) Develops therapeutic products for oncology that target telomerase; pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases.
MultiCell (OTCBB: MCET)
Developer of therapeutic products, an adult stem cell company and a supplier of immortalized human cell lines for drug discovery applications.

Stem Cell Thera (TSX.V: SSS)
A biotechnology company focused on the development of its technology platform and intellectual property to selectively induce a patient’s own stem cells to proliferate in the brain.

Stem Cells (Nasdaq: STEM)
Developer of stem cell therapeutics to treat damage to or degeneration of major organ systems such as the central nervous system, liver and pancreas.

ThermoGenesis (Nasdaq: KOOL)
Provides Healthcare professionals with the means to micro-manufacture potentially life-saving and life-enhancing products from individual units of blood.

Buzz Stock of the day- ARAY

Thursday, March 5th, 2009


Companies with disruptive technologies always pop up on our radar. We keep a close eye on them until we start seeing some traction for their products, and then do a little more digging to see if the company has what it takes to be a Buzz Stock.

We’ve had our eye on Accuray, Inc. (Nasdaq: ARAY) for quite some time. The company’s non-invasive CyberKnife Robotic Radiosurgery System has received recognition from both physicians, and customers as of late.

On March 2, Accuray issued a news release that announced “increased interest and continued rapid growth” for CyberKnife. According to the announcement, the number of lung cancer patients treated with CyberKnife grew 52 percent from 2007-2008 in the U.S., and 43 percent worldwide. Additionally the overall number of patients treated with CyberKnife radiosurgery grew to more than 60,000 patients – a 14 percent increase from calendar year 2007 to 2008. In late February, the stock received a 5-star rating from members of the Motley Fool’s CAPS community. The Company has a CAGR of about 52 percent over the past two years and about $110 million of cash in the bank. Currently trading at around $4.00 a share, Accuray could be a good buy at these levels.

Check out this video on CyberKnife to get a better idea of why Accuray is our Buzz Stock of the day.

Top ETFs for 2009 YouTube Video

Saturday, February 14th, 2009

If you cant view the above. Try to check it out on google video here http://video.google.com/videoplay?docid=-4242486558099610171
OR

Top ETFs for 2009- VBK, SDY, DLN and ITM

Monday, February 9th, 2009

ETFs are a great way to go for anyone looking to plug holes in their portfolio. If you’re looking for more exposure to foreign markets or can’t decide which biotech stock to invest in, maybe an ETF is the way to go. A lot of experts are pointing to ETFs as a good way for investors to get back some of their lost gains.

Here are a few differences between an ETF and an index fund.

Taxes: The big buzz about ETFs is their tax efficiency. The big “tax event” for ETF shareholders happens when you sell your shares, hopefully at a profit, after which you’ll pay capital gains taxes.

Expense ratios: By construction, ETF investors have less exposure to capital gains taxes than mutual fund shareholders. That’s because fund managers frequently buy and sell the fund’s holdings — and ask investors to pick up the tab. ETFs occasionally shift shares, too, although much less than most mutual funds. Annual expenses for ETFs range between 0.1% and 0.65% and are deducted from dividends. Index mutual funds charge anywhere from 0.1% to more than 3%.

Minimum investment requirement: For investors with limited funds (say, less than $1,000) who want to get started in the stock market, ETFs offer a cheap entrée. Through your discount brokerage account, you can buy one single measly share if you choose. In comparison, many index mutual funds have high initial balance requirements. (Those with lower requirements often charge higher fees.)

Ease of use: Here’s the double-edged sword of ETF investing. They are easy to buy — you simply need a discount brokerage account (and that’s easy to get — and cheap). Consequently, they’re easy to trade. And trade and trade and trade.

Here are a few ETFs we think are worth keeping an eye on:

1. Vanguard Small Cap Growth ETF (VBK): Although the year-to-date returns were -40%, we think small-caps may lead the charge of the next bull market. Roughly 19% of this ETF’s holdings are in healthcare and industrial materials–both reasonably stable sectors. Holdings include: Devry, Inc. (NYSE: DV), Edwards Lifesciences (NYSE: EW) and ANSYS, Inc. (Nasdaq: ANSS).

2. SPDR S&P Dividend (SDY): Dividend ETFs seem to be gaining a lot of interest lately. This investment seeks to replicate, before expenses, correspond generally to the price and yield of the S&P High Yield Dividend Aristocrats index. The fund uses a passive management strategy designed to track the price and yield performance of the Dividend index. It is nondiversified.SDY has been down almost 23% over the last 12 months. However, its holdings, which include Con Edison (NYSE: ED), FirstMerit Corp. (Nasdaq: FMER) and Vectren Corp. (NYSE: VVC), all of which we think are in sweet spots of the market.

3. WisdomTree LargeCap Dividend (DLN): Another dividend ETF. DLN’s holdings include Chevron Corp. (NYSE: CVX), Pfizer, Inc. (NYSE: PFE), and Wal Mart Stores (NYSE: WMT). he fund employs a passive management (or indexing) investment approach designed to track the performance of the WisdomTree LargeCap Dividend index. It attempts to invest all, or substantially all, of assets in the stocks that make up the Index. DLN generally uses a replication strategy to achieve its investment objective and generally will hold each stock in approximately the same proportion as its weighting in the index. It is nondiversified.

4. Market Vectors Intermediate Municipal (ITM): The fund invests at least 80% of total assets in fixed-income securities that comprise the index. It has adopted a fundamental investment policy to invest at least 80% of assets in investments suggested by its name.

Here’s a cool video on ETF investing:

Stem Cell Buzz Stocks- STEM, GERN and ISCO

Monday, January 26th, 2009

Last Friday, the BBC reported that U.S. regulators have cleared the way for the world’s first study on human embryonic stem cell therapy.

After months of consideration, the FDA gave the go-ahead for the test. The approval of the 21,000 page application came days after President Barack Obama’s inauguration. Although the FDA’s decision is independent of White House Control, many are expecting Obama to adopt a more pragmatic and science-oriented approach to stem cell research than his predecessor.

Embryonic stem cells are unspecialized cells capable of turning into a wide variety of other cells. They are collected by cloning embryos in a laboratory, but the embryo is destroyed in the process. They were a hotly contended issue throughout George W. Bush’s presidency, with a ban on public research funding.

Here are a few buzz stocks specializing in stem cell research:

1. Stem Cells, Inc. (Nasdaq: STEM)– The Palo Alto-based company just received FDA approval to begin a clinical trial of a product candidate to treat Pelizaeus-Merzbacher Disease (PMD), a fatal brain disorder that affects young children. The company has a pro forma cash balance of about $40 million, counting the $20 million equity financing it just closed.

2. Geron Corp. (Nasdaq: GERN) – The company whose 21,000 page application was approved by the FDA. Geron plans to begin testing a treatment using embryonic stem cells that could fix major spinal cord injuries in people. Although the initial study is small, and will mainly focus on safety, the development process is expected to set the tone for this kind of research, how the FDA looks at it, and the pricing of any drugs that may result from it.

3. International Stem Cell Corp (OTCBB: ISCO)– The company just received the second $1 million tranche under a $5 million financing. ISCO’s “Parthenogenesis” technology results in the creation of cell lines that may allow cells from a single donor to be immune-matched to hundreds of millions of people. This could potentially reduce a lot of the dangers associated with immune rejection–a big problem with using embryonic stem cells.

Here’s a cool video explaining why the FDA approval is so significant: